Monday, 24 Jun 2019

You are here

RheumNow Podcast – Richer or Poorer (5.17.19)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com

  1. Public health study from Norway compares the top 1% richest and bottom 1% poorest found significant difference in life expectancy -14 years for men and 8 years for women. Similar USA study finds roughly the same as in Norway. https://t.co/h1QFZmgXaJ 
  2. Large study from OTIS on PsA and AS shows an increased risk for adverse pregnancy outcomes - including preterm delivery (RR 1.81, 3.82) & Cesarean delivery (RR 1.63, 5.82). Active disease & steroid use may also increase these risks. https://buff.ly/30lTKqI 
  3. Literature review - 23 studies on Natural dietary supplement (NDS) use finds that worldwide 47% of RA pts use NDS, did not differ by geographic region, 47% found NDS to be effective, 13% had adverse side effects, & 30% informed their physicians. https://t.co/N2O16NxuxU 
  4. Reactivation of latent CMV infection is rare in Rheum Pts. 14 pts described w/ febrile illness, on steroids (13), with coinfections (8), 4 died during hospitalization, tend to have longer hospitalizations (47 vs. 7 days), more coinfections (67% vs. 17%) https://t.co/pijtFv55Uq   
  5. Overall prevalence of low back pain among US workers is 26.4%, with 5.6% having severe LBP, according to May 14th Annals of Internal Medicine. https://t.co/5sfYFQWHyh   
  6. PCSK9 inhibitors (ie, Repatha) can safetly be used in Statin-induced HMGCR+ myopathy pts . 8 pts given PCSK9 inhib for hyperlipidemia, showed no Sx worsening, CK levels dropped (956±1137 IU/L to 419±393 IU/L) & HMGCR Ab titers decreased; 2/8 improved https://t.co/iSuPz6ptBY 
  7. Studies argue about MTX efficacy in GCA; many calling for new RCTs at higher doses. A new real world study compared 83 GCA pts on MTX (13.5mg/wk) vs 83 controls showing signif. lower relapse rates with MTX (0.32; 0.24–0.41), but no change in steroid use https://t.co/aCrL4PILUM
  8. DECT is most accurate in diagnosing established gout - review of 10 studies shows a pooled (95% CI) sensitivity of 0.81 (0.77, 0.86) and specificity of 0.91 (0.85, 0.95), respectively. W/ short disease duration (⩽6 wks), sensitivity 0.55 and spec 0.89  https://buff.ly/2Ecw1Qg 
  9. Medicare analysis shows Gout patients are twice as likely to have chronic pain (HR 2.02; 95% CI 1.98-2.05) and use of allopurinol or febuxostat was associated with a lower risk of chronic pain (HR 0.72-0.79) https://t.co/xW5rVPyC69 
  10. Coexistent Gout Increases Risk in Rheumatoid Arthritis  
  11. Methotrexate Use Not Linked to Interstitial Lung Disease in RA  
  12. Generic Price Fixing Alleged by State Prosecutors   

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

RheumNow Podcast – Late Breaking Abstract Wrap-Up (6.21.19)

Dr. Jack Cush reviews the week’s news and wrap up from EULAR19.

EULAR 2019 - Podcast #1

This EULAR 2019 Podcast is a compilation of audio clips from EULAR 2019 in Madrid.

 

Click HERE to listen.

 

You can also listen on iTunes, Soundcloud or Stitcher.

ACP Guidelines on Developing Evidence Based Clinical Guidelines

Recommendations for the screening, diagnosis, and treatment of various diseases often differ by organization, making it difficult to know which ones to follow.

EULAR 2019- Day 4 Report

Saturday June 15th was the last half-day at EULAR 2019 but was highlighted by the “late-breaking” (LB) presentations that were presented from the podium and by poster.

Below are the top “LB” presentations from EULAR this year:

Understanding Non-arthritic Rheumatic iRAEs

A better understanding of rheumatic immune-related adverse event phenotypes beyond inflammatory arthritis has been furthered by work from three abstracts presented at EULAR 2019 in Madrid.